annb0t
Top 20
ResMed Inc (NYSE: RMD) posted Q4 sales of $914.7 million, +4% Y/Y (+8% on a constant currency basis), beating the consensus of $912.97 million. Adjusted EPS reached $1.49, up from $1.35 a year ago. The company also increased its quarterly dividend to $0.44 from $0.42 per share. Keybanc reiterates the Overweight rating and price target of $276. The analyst says that after resetting near-term supply chain expectations, visibility appears to be increasing and management's tone seemed more optimisti...
>>> Read more: Competitor Recall Continues To Show Opportunities For ResMed
>>> Read more: Competitor Recall Continues To Show Opportunities For ResMed
